Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 309 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: VIGAMOX Clear all

Conditions: Conjunctivitis
Interventions: moxifloxacin, polytrim; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 1 Year to 18 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Healthy
Interventions: granisetron; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Alzheimer's Disease
Interventions: AZD3293, Placebo, Moxifloxacin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy
Interventions: Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Anti-biotic Resistance
Interventions: moxifloxacin 0.5% HCI ophthalmic solution, gatifloxacin ophthalmic solution 0.3%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Volunteer
Interventions: ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: San Diego, California • Tacoma, Washington

Conditions: Community-Acquired Bacterial Pneumonia (CABP)
Interventions: Nafithromycin 800 mg 3 days, Nafithromycin 800 mg 5 days, Moxifloxacin 400 mg; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Miami, Florida • Miami Lakes, Florida • Bedford, Massachusetts + 1 more

Conditions: Acute Coronary Syndrome
Interventions: Losmapimod, Moxifloxacin, Losmapimod matched Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: MK-8527, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Healthy
Interventions: sisunatovir, placebo, moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Acne Vulgaris
Interventions: SB204 4%, SB204 8% or 12%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Infection, Human Immunodeficiency Virus
Interventions: Ortho-Cyclen, Dolutegravir, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Fibrillation, Atrial, Atrial Fibrillation
Interventions: Odiparcil; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cataract
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1%; Drug
Lead sponsor: Wyse Eyecare; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Northbrook, Illinois

Conditions: Cataract Extraction
Interventions: Besifloxacin hydrochloride, moxifloxacin hydrochloride, gatifloxacin; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Rockville Centre, New York

Conditions: Cardiac Repolarization in Healthy Subjects
Interventions: TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208, Moxifloxacin 400 mg; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: BMS-986278, Placebo, Moxifloxacin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cardiodynamics, Safety, Tolerability, Pharmacokinetics
Interventions: selexipag, placebo for selexipag, moxifloxacin, moxifloxacin-matching placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 159 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Obstetric Labour, Premature
Interventions: Retosiban 100 mg, Retosiban 800 mg, Placebo, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Patient Preference
Interventions: Dexamethasone, Standard of care surgery; Drug · Other
Lead sponsor: Ophthalmic Consultants of Long Island; Other
Eligibility: 22 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Garden City, New York

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Search by objective public record fields.

Moxifloxacin vs. Polytrim for Conjunctivitis

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

AZD3293 Thorough QT Study in Healthy Male Volunteers

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

Drug Interaction - Oral Contraceptive

Phase II Study of Oral Nafithromycin in CABP

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)

A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants.

A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204

Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol

Odiparcil QT Definitive Study

A Study for Post op Inflammation After Cataract Surgery

Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy Participants

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.

A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia